Jacobs Levy Equity Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Jacobs Levy Equity Management's REGN Position: Q2 2026 in Review
Jacobs Levy Equity Management increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, buying an estimated $28.8M and bringing the position to 256,503 shares worth $160M. The position accounts for 0.58% of the portfolio, ranked #36.
Jacobs Levy Equity Management first reported a position in REGN in Q1 2016 and has held it in 15 quarters since. The position peaked at $205M in Q4 2025. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Jacobs Levy Equity Management held 256,503 shares of Regeneron Pharmaceuticals worth $160M as of Q2 2026.
- Jacobs Levy Equity Management bought 42,343 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $28.8M.
- Regeneron Pharmaceuticals made up 0.58% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #36 holding.
- Jacobs Levy Equity Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 15 quarters since.
- Jacobs Levy Equity Management's Regeneron Pharmaceuticals position peaked at $205M in Q4 2025.
- 1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.